Literature DB >> 23199500

Natural history of acute and chronic hepatitis C.

Benjamin Maasoumy1, Heiner Wedemeyer.   

Abstract

Hepatitis C virus (HCV) infection remains a major global health burden. Hepatitis C causes significant liver-related morbidity and mortality due to hepatic decompensation and development of hepatocellular carcinoma. In addition, extra-hepatic manifestations of hepatitis C are frequent. There is a very large interindividual variability in the natural history of both acute and chronic hepatitis C which can be explained in part by a combination of various host, viral and environmental factors. Successful antiviral treatment can prevent short- and long-term complications of HCV infection in many patients. Still, the relative contribution of distinct risk factors for disease progression in different phases of HCV infection needs to be better defined. Personalized treatment approaches for HCV infection should consider individual risk profiles to avoid both under- and over-treatment - which will remain important also in upcoming era of interferon-free treatment of hepatitis C.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23199500     DOI: 10.1016/j.bpg.2012.09.009

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  69 in total

1.  Innate immune response induced by baculovirus attenuates transgene expression in mammalian cells.

Authors:  Chikako Ono; Akinori Ninomiya; Satomi Yamamoto; Takayuki Abe; Xiauyu Wen; Takasuke Fukuhara; Miwa Sasai; Masahiro Yamamoto; Tatsuya Saitoh; Takashi Satoh; Taro Kawai; Ken J Ishii; Shizuo Akira; Toru Okamoto; Yoshiharu Matsuura
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

2.  Natural evolution of hepatitis C virus infection in hemodialysis Tunisian patients and CTLA-4 SNP's.

Authors:  Leila Ksiaa Cheikhrouhou; Yousr Lakhoua-Gorgi; Imen Sfar; Salwa Jendoubi-Ayed; Houda Aouadi; Mouna Makhlouf; Khaled Ayed; Taieb Ben Abdallah
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

Review 3.  [New direct-acting antiviral agents for the treatment of chronic hepatitis C in 2014].

Authors:  M Cornberg; C Höner zu Siederdissen; B Maasoumy; M P Manns
Journal:  Internist (Berl)       Date:  2014-04       Impact factor: 0.743

4.  USP15 Participates in Hepatitis C Virus Propagation through Regulation of Viral RNA Translation and Lipid Droplet Formation.

Authors:  Shinji Kusakabe; Tatsuya Suzuki; Yukari Sugiyama; Saori Haga; Kanako Horike; Makoto Tokunaga; Junki Hirano; He Zhang; David Virya Chen; Hanako Ishiga; Yasumasa Komoda; Chikako Ono; Takasuke Fukuhara; Masahiro Yamamoto; Masahito Ikawa; Takashi Satoh; Shizuo Akira; Tomohisa Tanaka; Kohji Moriishi; Moto Fukai; Akinobu Taketomi; Sachiyo Yoshio; Tatsuya Kanto; Tetsuro Suzuki; Toru Okamoto; Yoshiharu Matsuura
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

5.  Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients.

Authors:  Shu-Fen Wu; Chih-Wei Tseng; Yun-Che Ho; Yen-Chun Chen; Ping-Hung Ko; Yi-Ting He; Kuo-Chih Tseng
Journal:  Dig Dis Sci       Date:  2019-09-26       Impact factor: 3.199

6.  Characterization of SPP inhibitors suppressing propagation of HCV and protozoa.

Authors:  Junki Hirano; Toru Okamoto; Yukari Sugiyama; Tatsuya Suzuki; Shinji Kusakabe; Makoto Tokunaga; Takasuke Fukuhara; Miwa Sasai; Takahiro Tougan; Yasue Matsunaga; Kazuo Yamashita; Yusuke Sakai; Masahiro Yamamoto; Toshihiro Horii; Daron M Standley; Kohji Moriishi; Kyoji Moriya; Kazuhiko Koike; Yoshiharu Matsuura
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-29       Impact factor: 11.205

7.  Retreatment with peginterferon and ribavirin in chronic hepatitis C.

Authors:  Yong Min Jo; Sung Wook Lee; Sang Young Han; Yang Hyun Baek; Soo Young Kim; Woo Jae Kim; Ji Hye Ahn; Ji Young Lee
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 8.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

9.  Human Cathelicidin Compensates for the Role of Apolipoproteins in Hepatitis C Virus Infectious Particle Formation.

Authors:  Francesc Puig-Basagoiti; Takasuke Fukuhara; Tomokazu Tamura; Chikako Ono; Kentaro Uemura; Yukako Kawachi; Satomi Yamamoto; Hiroyuki Mori; Takeshi Kurihara; Toru Okamoto; Hideki Aizaki; Yoshiharu Matsuura
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

Review 10.  Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients.

Authors:  Evangelos Cholongitas; Chrysoula Pipili; George Papatheodoridis
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.